# Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients

> **NCT07679841** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 50 (estimated)

## Conditions studied

- Vulvar Squamous Cell Carcinoma

## Interventions

- **DRUG:** Imiquimod 5% cream
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07679841
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679841, "Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*